Background
Methods
Participants
Follow-up study
Definition of clinical parameters and outcomes
Statistical analysis
Results
Clinical characteristics of participants at baseline
History of LEA at baseline | p | ||
---|---|---|---|
No | Yes | ||
N (%) | 968 (90.7) | 99 (9.3) | |
Male sex (%) | 51.9 | 70.7 | 0.0003 |
Age (years) | 42.6 ± 11.6 | 51.6 ± 11.2 | <0.0001 |
Age at diabetes onset (years) | 15.5 ± 9.1 | 18.3 ± 9.0 | 0.007 |
Duration of diabetes (years) | 27.0 ± 9.3 | 33.3 ± 9.0 | <0.0001 |
Body mass index (kg/m2) | 24.1 ± 3.5 | 23.9 ± 3.8 | 0.40 |
Systolic BP (mmHg) | 134 ± 19 | 143 ± 20 | <0.0001 |
Diastolic BP (mmHg) | 77 ± 11 | 80 ± 11 | 0.003 |
HbA1c (%) and (mmol/mol) | 8.5 ± 1.5 (70 ± 16) | 8.8 ± 2.1 (72 ± 23) | 0.31 |
Plasma creatinine (µmol/l) | 113 ± 112 | 166 ± 163 | <0.0001 |
eGFR (ml/min/1.73 m2) | 81 ± 44 | 60 ± 37 | <0.0001 |
UAC (mg/l) | 22 (238) | 95 (499) | 0.01 |
Total cholesterola (mmol/l) | 5.70 ± 1.45 | 5.67 ± 1.45 | 0.68 |
Triglyceridesa (mmol/l) | 1.13 (0.91) | 1.29 (0.5) | 0.31 |
Tobacco smokingb (%) | 42.3 | 55.1 | 0.01 |
Antihypertensive drugs (%) | 51.1 | 73.7 | <0.0001 |
ACE-I or ARB drugs (%) | 41.3 | 55.6 | 0.006 |
Lipid lowering drugs (%) | 8.4 | 11.1 | 0.35 |
Diabetic nephropathy stages (%) | 46/21/18/15 | 18/17/30/35 | <0.0001 |
Diabetic retinopathy stages (%) | 0/27/18/55 | 0/4/15/81 | <0.0001 |
Peripheral sensory neuropathy (%) | 46.4 | 89.7 | <0.0001 |
Peripheral artery disease (%) | 5.8 | 93.8 | <0.0001 |
LEA and kidney and cardiovascular complications at baseline
LEA and clinical outcomes during follow-up
Clinical outcomes during follow-up | ||||||
---|---|---|---|---|---|---|
ESRD | Myocardial infarction | Stroke | ||||
No | Yes | No | Yes | No | Yes | |
LEA at baseline | ||||||
No | 644 (93.1 %) | 48 (6.9 %) | 697 (95.5 %) | 33 (4.5 %) | 698 (97.1 %) | 21 (2.9 %) |
Yes | 44 (86.3 %) | 7 (13.7 %) | 43 (72.9 %) | 16 (27.1 %) | 51 (91.1) | 5 (8.9 %) |
HR (95 % CI) model 1 | 2.69 (1.17–6.20) | 3.53 (1.79–6.97) | 1.76 (0.60–5.14) | |||
P | 0.02 | 0.0001 | 0.29 | |||
HR (95 % CI) model 2 | 2.49 (1.02–6.06) | 3.21 (1.50– 6.85) | 1.28 (0.37–4.43) | |||
P | 0.04 | 0.003 | 0.69 | |||
SHR (95 % CI) model 3 | 2.41 (1.04–5.87) | 3.16 (1.53–6.52) | 1.49 (0.46–4.84) | |||
P | 0.04 | 0.002 | 0.50 |
LEA at baseline and mortality during follow-up
All-cause mortality | Cardiovascular mortality | Infectious disease mortality | Other causes of mortality | |||||
---|---|---|---|---|---|---|---|---|
No | Yes | No | Yes | No | Yes | No | Yes | |
LEA at baseline | ||||||||
No | 691 (93.6 %) | 47 (6.4 %) | 691 (97.5 %) | 18 (2.5 %) | 691 (99.0 %) | 7 (1.0 %) | 691 (96.9 %) | 22 (3.1 %) |
Yes | 36 (59.0 %) | 25 (41.0 %) | 36 (78.3 %) | 10 (21.7 %) | 36 (92.3 %) | 3 (7.7 %) | 36 (75.0 %) | 12 (25.0 %) |
HR (95 % CI) model 1 | 3.55 (2.05–6.16) | 4.04 (1.69–9.62) | 3.28 (0.73 –14.68) | 3.25 (1.44–7.30) | ||||
P | <0.0001 | 0.002 | 0.12 | 0.004 | ||||
HR (95 % CI) model 2 | 2.73 (1.49–5.01) | 3.30 (1.36–8.02) | 5.18 (1.13–23.84) | 2.81 (1.09–7.26) | ||||
P | 0.001 | 0.008 | 0.03 | 0.03 |